权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

PET to Measure Breast Cancer Bone Metastasis Response

PET 测量乳腺癌骨转移反应

基本信息

批准号：
7318954
负责人：
DAVID A. MANKOFF
金额：
$ 36.24万
依托单位：
UNIVERSITY OF WASHINGTON
依托单位国家：
美国
项目类别：
财政年份：
2007
资助国家：
美国
起止时间：
2007-07-01 至 2012-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7318954
关键词：
Appearance Behavior Biologic Characteristic Biology Biopsy Bone Regeneration Bone neoplasms Bone remodeling Cancer Patient Characteristics Clinical Clinical Trials Early Intervention Energy Metabolism Equilibrium Event Exhibits Flare Fluorides Fracture Goals Gold Healed Hormone Receptor Image Investigation Kinetics Lesion Lytic Lytic Lesion Mammary Neoplasms Measures Metabolism Metastatic Neoplasm to the Bone Methods Nature Neoplasm Metastasis Osteolytic Outcome Outcome Measure PET/CT scan Patients Physiologic calcification Positron-Emission Tomography Primary Neoplasm Property Prospective Studies Proteins Rate Reaction Time Relative (related person)Research Personnel Retrospective Studies Risk Serum Site Skeletal system Standards of Weights and Measures Systemic Therapy Testing Time Tumor necrosis factor receptor 11b Urine Visceral base bisphosphonate bone bone healing bone imaging bone turnover chemotherapy fluorodeoxyglucose positron emission tomography healing hormone therapy in vitro Assay in vivo indexing malignant breast neoplasm outcome forecast prevent programs response size tumor uptake

项目摘要

DESCRIPTION (provided by applicant): Bone is a common site of metastasis for breast cancer. Although rarely "cured" of breast cancer, patients with bone-dominant breast cancer have a more favorable prognosis than patients with visceral involvement and may have prolonged survival. These patients benefit from an increasing array of effective therapies; however, the choice of therapy is hampered by the difficulty of assessing response. We have shown, in retrospective studies, that serial FDG PET can measure bone metastasis response to therapy, that changes in FDG uptake with treatment predict time-to-progression (TTP), and that the level of FDG uptake predicts the likelihood of skeletal-related events (SRE), such as fracture. We have also used 18F-fluoride PET to assess tumor effect on the1 bone adjacent to metastases and have shown that the information gained on bone metastasis behavior from fluoride PET is distinct from and complementary to FDG PET. We now propose to extend these preliminary studies to a larger prospective study of FDG and fluoride PET in patients with bone-dominant breast cancer undergoing systemic therapy. Our aims are (1) to prospectively validate FDG and fluoride PET as measures of bone metastasis response to therapy with patient outcome as the gold standard, (2) to measure the in vivo biology of metastatic sites and adjacent bone using a combination of quantitative FDG PET/CT and fluoride PET with the goal of predicting the risk of a skeletal event and also to relate PET measures to tumor characteristics measured by in vitro assay of biopsy material, and (3) to measure the early effect of bisphosphonates on bone turnover using fluoride PET to better understand the in vivo effect of these agents, which are almost universally used in treating breast cancer metastases. The result of these investigations will be imaging methods, validated by patient outcome, for measuring breast cancer bone metastasis response in clinical trials and clinical practice and for directing appropriate early interventions to prevent skeletal events.

描述（由申请人提供）：骨是乳腺癌常见的转移部位。尽管乳腺癌很少“治愈”，但骨为主型乳腺癌患者的预后比内脏受累患者更好，并且可能延长生存期。这些患者受益于越来越多的有效疗法；然而，治疗的选择因难以评估疗效而受到阻碍。我们在回顾性研究中表明，连续 FDG PET 可以测量骨转移对治疗的反应，治疗中 FDG 摄取的变化可以预测进展时间 (TTP)，FDG 摄取水平可以预测骨骼相关事件 (SRE)（例如骨折）的可能性。我们还使用 18F-氟化物 PET 来评估肿瘤对邻近转移灶的骨的影响，并表明从氟化物 PET 中获得的骨转移行为信息与 FDG PET 不同且互补。我们现在建议将这些初步研究扩展到对接受全身治疗的骨为主型乳腺癌患者进行 FDG 和氟化物 PET 的更大规模前瞻性研究。我们的目标是 (1) 前瞻性地验证 FDG 和氟化物 PET 作为衡量骨转移对治疗的反应的指标，以患者结果作为金标准，(2) 使用定量 FDG PET/CT 和氟化物 PET 的组合来测量转移部位和邻近骨的体内生物学，目的是预测骨骼事件的风险，并将 PET 测量与体外测量的肿瘤特征联系起来 (3) 使用氟化物 PET 测量双磷酸盐对骨转换的早期影响，以更好地了解这些药物的体内效果，这些药物几乎普遍用于治疗乳腺癌转移。这些研究的结果将是通过患者结果验证的成像方法，用于在临床试验和临床实践中测量乳腺癌骨转移反应，并指导适当的早期干预措施以预防骨骼事件。